Clario Expands Neuroscience Expertise with NeuroRx Acquisition
Deal News | Mar 17, 2025 | PR Newswire Cision Clario
On March 17, 2025, Clario, a leading provider of endpoint data solutions in the clinical trial industry, announced the acquisition of NeuroRx, an imaging analysis firm recognized for its expertise in multiple sclerosis. The strategic acquisition aligns with Clario's expansion in the neuroscience domain, enhancing its capabilities in a critical therapeutic area. NeuroRx, known for its contributions to more than 300 clinical trials and the approval of 12 FDA-marketed multiple sclerosis treatments, will strengthen Clario's service offerings. Dr. Douglas Arnold, NeuroRx's founder and CEO, will join Clario as Senior Scientific Advisor. Furthermore, Clario announced an agreement to acquire WCG's eCOA business to bolster its neuroscience service delivery capabilities. Over the years, Clario has delivered services critical to transforming neurological and therapeutic medicine globally, bolstered by the support of shareholders such as Astorg, Nordic Capital, Novo Holdings, and Cinven.
Sectors
- Healthcare & Biotechnology
- Medical Imaging Technologies
- Pharmaceuticals
Geography
- United States – The acquisition announcement by Clario, headquartered in Philadelphia, illustrates the significant movements in the healthcare sector within the U.S.
- Global – With NeuroRx having supported clinical studies in 82 countries and Clario's wide reach, the acquisition reflects a global impact in the clinical trials and medical imaging industries.
Industry
- Healthcare & Biotechnology – The article discusses Clario's acquisition of NeuroRx, which focuses on imaging solutions and neurological clinical trials, areas directly related to the healthcare and biotech industry.
- Medical Imaging Technologies – The acquisition further reinforces the role of imaging technologies in medical trials, with NeuroRx's impressive track record supporting clinical studies being a central theme.
- Pharmaceuticals – Clario and NeuroRx's collaboration supports drug development, particularly highlighting NeuroRx's role in multiple FDA drug approvals for neurological conditions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Clario | Acquirer | Company | A leading provider of endpoint data solutions for the clinical trials industry, enhancing its capabilities in neuroscience and imaging. |
| NeuroRx | Target | Company | An imaging provider specializing in neurological diseases, with a strong influence in FDA-approved multiple sclerosis drugs. |
| Chris Fikry | CEO of Clario | Person | Leads Clario and comments on the strategic importance of acquiring NeuroRx for neuroscience development. |
| Douglas Arnold | Founder & CEO of NeuroRx | Person | Joining Clario as Senior Scientific Advisor, highlighting the integration of NeuroRx expertise into Clario. |
| Joyce Suhy | Executive VP of Medical Imaging and Specialty Solutions at Clario | Person | Articulates the significance of NeuroRx's expertise in enhancing Clario's neuroscience initiatives. |
| Astorg | Shareholder of Clario | Company | One of Clario's controlling shareholders. |
| Nordic Capital | Shareholder of Clario | Company | One of Clario's controlling shareholders. |
| Novo Holdings | Shareholder of Clario | Company | One of Clario's controlling shareholders. |
| Cinven | Shareholder of Clario | Company | One of Clario's controlling shareholders. |
| WCG | Future Acquisition Target | Company | Clario announced an agreement to acquire WCG's eCOA business, further solidifying its capabilities. |